Literature DB >> 18259944

TAE226 inhibits human neuroblastoma cell survival.

Elizabeth A Beierle1, Angelica Trujillo, Abhilasha Nagaram, Vita M Golubovskaya, William G Cance, Elena V Kurenova.   

Abstract

PURPOSE: Neuroblastoma is one of the most devastating pediatric solid tumors and is unresponsive to many interventions. TAE226 is a novel small molecule FAK inhibitor. We investigated the effects of TAE226 on neuroblastoma cells in vitro.
MATERIALS AND METHODS: Human neuroblastoma cell lines were treated with varying concentrations of TAE226. Following treatment, cell viability, cell cycle, and apoptosis were evaluated.
RESULTS: Treatment of human neuroblastoma cell lines with TAE226 resulted in a concentration dependent decrease in FAK phosphorylation, decrease in cellular viability, cell cycle arrest, and an increase in apoptosis.
CONCLUSIONS: Targeting FAK provides potential therapeutic options for the treatment of neuroblastoma and deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18259944     DOI: 10.1080/07357900701577475

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  16 in total

1.  Focal adhesion kinase inhibitors are potent anti-angiogenic agents.

Authors:  Miguel A Cabrita; Laura M Jones; Jennifer L Quizi; Luc A Sabourin; Bruce C McKay; Christina L Addison
Journal:  Mol Oncol       Date:  2011-10-20       Impact factor: 6.603

Review 2.  Cell survival signaling in neuroblastoma.

Authors:  Michael L Megison; Lauren A Gillory; Elizabeth A Beierle
Journal:  Anticancer Agents Med Chem       Date:  2013-05       Impact factor: 2.505

Review 3.  The 2016 John J. Abel Award Lecture: Targeting the Mechanical Microenvironment in Cancer.

Authors:  Hannah E Majeski; Jing Yang
Journal:  Mol Pharmacol       Date:  2016-10-14       Impact factor: 4.436

Review 4.  Targeting focal adhesion kinase in neuroblastoma.

Authors:  Lauren Gillory; Elizabeth A Beierle
Journal:  Anticancer Agents Med Chem       Date:  2010-12       Impact factor: 2.505

Review 5.  Focal adhesion kinase as a cancer therapy target.

Authors:  Vita M Golubovskaya
Journal:  Anticancer Agents Med Chem       Date:  2010-12       Impact factor: 2.505

Review 6.  Targeting cytoskeleton reorganisation as antimetastatic treatment.

Authors:  Miguel Quintela-Fandino; Antonio González-Martín; Ramon Colomer
Journal:  Clin Transl Oncol       Date:  2010-10       Impact factor: 3.405

7.  Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.

Authors:  Elizabeth A Beierle; Xiaojie Ma; Jerry E Stewart; Michael Megison; William G Cance; Elena V Kurenova
Journal:  Mol Carcinog       Date:  2012-10-12       Impact factor: 4.784

8.  Mesenchymal migration as a therapeutic target in glioblastoma.

Authors:  Jessie Zhong; Andre Paul; Stewart J Kellie; Geraldine M O'Neill
Journal:  J Oncol       Date:  2010-06-21       Impact factor: 4.375

9.  FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma.

Authors:  Michael L Megison; Jerry E Stewart; Hugh C Nabers; Lauren A Gillory; Elizabeth A Beierle
Journal:  Clin Exp Metastasis       Date:  2012-12-04       Impact factor: 5.150

10.  Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.

Authors:  Jerry E Stewart; Xiaojie Ma; Michael Megison; Hugh Nabers; William G Cance; Elena V Kurenova; Elizabeth A Beierle
Journal:  Mol Carcinog       Date:  2013-07-19       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.